Clinical trial NCT06429176: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis
Official title: A Phase 2a, Randomized, Placebo-Controlled, Double Blind Multiple Ascending Dose Study in Patients with Cystic Fibrosis Carrying the 3849 +10 Kb C->T Mutation to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Cystic Fibrosis
Lead sponsor: SpliSense Ltd.
Sponsor class: INDUSTRY
First posted: 2024-05-24
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to learn if drug SPL84 is safe for adult patients with cystic fibrosis (CF). It will also learn if the drug works to treat works to treat CF with a specific mutation.

The purpose of this research study is to:

* test the safety and effectiveness of multiple doses of the study drug, SPL84
* test how multiple doses of the drug are processed by the body

Researchers will compare drug SPL84 to a placebo (a look-alike substance that contains no drug) to see if drug SPL84 is safe and if it works to treat CF.

Participants will:

Take drug SPL84 or a placebo by inhalation every week for 9 weeks months Visit the clinic approximately 14 times over 17.5 weeks for checkups and tests


Eligibility criteria: Inclusion Criteria:

* Diagnosis of CF and two CF causing mutations; 3849+10 Kb C-\>T mutation on one allele in the CF transmembrane conductance regulator (CFTR) gene (homozygote or compound heterozygote). Source documentation from a certified genetic laboratory is required.
* Body mass index (BMI) of ≥ 17 kg/m2.
* FEV1 40-90% predicted at screening.
* Non-smokers or vapers for at least 180 days (6 months) prior to screening, per participant report.

Exclusion Criteria:

* Use of Kalydeco, Orkambi, Symdeko/Symkevi or Trikafta/Kaftrio within 30 days of first dose with study intervention.
* Use of any investigational drug (other than SPL84) or device within 30 days of first dose with study intervention.
* Use of systemic steroids over 3 consecutive months in the last 6 months prior to screening, or use of systemic steroids in the last month prior to screening. Use of inhaled steroids above 1 mg.
* Use of CF medications, e.g. inhaled antibiotics, dornase alfa (Pulmozyme), hypertonic saline and physiotherapy should be on stable regimen for the period 28 days prior to screening; those participants taking inhaled antibiotics for prophylaxis must be on a stable regimen of these drugs for at least 90 days prior to first dose with study intervention.
* Any acute infection including acute upper respiratory or lower respiratory infections, pulmonary exacerbation, changes in therapy for pulmonary disease, or any non CF-related illness which results in the initiation of any new therapy within 14 days prior to first dose with study intervention.
* Hemoptysis of greater than 30 mL within 90 days prior to Day 1, or hospitalization for hemoptysis within 6 months of first dose with study intervention.
* Liver disease characterized by clinically significant cirrhosis and/or documented portal hypertension.
* History of any organ transplantation.
* Documented coronavirus disease (COVID-19) infection within 4 weeks prior to dosing.

Primary outcomes:
measure: Safety and Tolerability of SPL84 as evaluated by number of subjects with at least one treatment-related adverse event (AE) or serious adverse event (SAEs)
timeFrame: Day 1 through Day 87
measure: Safety and Tolerability of SPL84 as assessed by number of participants with abnormal heart rate
timeFrame: Day 1 through Day 87
measure: Safety and Tolerability of SPL84 as assessed by number of participants with abnormal respiratory rate
timeFrame: Day 1 through Day 87
measure: Safety and Tolerability of SPL84 as assessed by number of participants with abnormal systolic and diastolic blood pressure
timeFrame: Day 1 through Day 87
measure: Safety and Tolerability of SPL84 as assessed by number of participants with abnormal oximetry
timeFrame: Day 1 through Day 87
measure: Safety and Tolerability of SPL84 as assessed by number of participants with abnormal temperature
timeFrame: Day 1 through Day 87
measure: Safety and Tolerability of SPL84 as assessed by number of participants with abnormal hematology lab test results
timeFrame: Day 1 through Day 87
measure: Safety and Tolerability of SPL84 as assessed by number of participants with abnormal biochemistry lab test results
timeFrame: Day 1 through Day 87
measure: Safety and Tolerability of SPL84 as assessed by number of participants with abnormal urinalysis lab test results
timeFrame: Day 1 through Day 87
measure: Safety and Tolerability of SPL84 as assessed by number of participants with abnormal electrocardiogram (ECG) parameters
timeFrame: Day 1 through Day 87
measure: Safety and Tolerability of SPL84 as assessed by number of participants with abnormal physical examination findings
timeFrame: Day 1 through Day 87
measure: Safety and Tolerability of SPL84 as assessed by number of participants with abnormal pulmonary function tests results
timeFrame: Day 1 through Day 87
measure: Safety and Tolerability of SPL84 as assessed by number of participants with abnormal sputum microbiology results results
timeFrame: Day 1 through Day 87
measure: Safety and Tolerability of SPL84 as assessed by number of participants with abnormal immunogenicity results
timeFrame: Day 1 through Day 87
Secondary outcomes:
measure: Characterization of pharmacokinetics (PK) of SPL84: maximum serum concentration (Cmax)
timeFrame: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
measure: Characterization of PK of SPL84: Time to Cmax (Tmax)
timeFrame: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
measure: Characterization of PK of SPL84: terminal elimination half-life (t1/2)
timeFrame: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
measure: Characterization of PK of SPL84: Area under the curve to the final sample (AUC0-t)
timeFrame: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
measure: Characterization of PK of SPL84: Area under the curve to infinity (AUC0-∞)
timeFrame: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
measure: Characterization of PK of SPL84: Apparent clearance (CL/F)
timeFrame: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
measure: Characterization of excretion of SPL84: concentration of SPL84 in urine
timeFrame: Day 1 through Day 87
measure: Preliminary efficacy of SPL84 as assessed by change from baseline in percent predicted FEV1
timeFrame: Day 1 through Day 87
measure: Preliminary efficacy of SPL84 as assessed by change from baseline in Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score
timeFrame: Day 1 through Day 87
measure: Preliminary efficacy of SPL84 as assessed by change from baseline in body weight
timeFrame: Day 1 through Day 87
measure: Preliminary efficacy of SPL84 as assessed by change from baseline of antibiotic treatment
timeFrame: Day 1 through Day 87
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston Children'S Hospital
state: Massachusetts
city: Columbus
country: United States
facility: Nationwide Children'S Hospital
state: Ohio
Study officials:
References: